Table 4

Differences in relative improvement* effects toward the healthy population's mean value between the oral B12 treatment and placebo group (RΔ%) at 1 and 4 months

Relative improvement effect towards healthy population's mean value

Biological marker

1 month RΔ% (CI95%; p-value)

4 months RΔ% (CI95%; p-value)

MMA (μmol/l) Reduction

48.7% (CI95% 29.0:68.3; p < 0.001)

0.2% (CI95% -17.8:18.3; p = 0.979)

Serum cobalamin (pM/l) Increase

26.9% (CI95% 13.9:39.8; p < 0.001)

14.1% (CI95% -3.1:31.3; p = 0.105)

Hcys (μmol/l) Reduction

1.8% (CI95% -16.4:20.0; p = 0.844)

6.7% (CI95% -11.3:24.7; p = 0.455)

* Improvement from baseline compared to what would have been expected had the values become normal (MMA = 0.17 μmol/l, vitamin B12 = 375 pM/l, and Hcys = 10.2 μmol/l).

Favrat et al. BMC Family Practice 2011 12:2   doi:10.1186/1471-2296-12-2